Free Trial
NASDAQ:XNCR

Xencor Q1 2024 Earnings Report

Xencor logo
$10.50 +0.19 (+1.79%)
As of 10:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xencor EPS Results

Actual EPS
-$1.11
Consensus EPS
-$0.83
Beat/Miss
Missed by -$0.28
One Year Ago EPS
-$1.02

Xencor Revenue Results

Actual Revenue
$12.80 million
Expected Revenue
$23.07 million
Beat/Miss
Missed by -$10.27 million
YoY Revenue Growth
-32.30%

Xencor Announcement Details

Quarter
Q1 2024
Time
After Market Closes
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Xencor's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Tuesday, November 4, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xencor Earnings Headlines

Xencor (XNCR) Receives a Sell from Roth MKM
Wall Street laughed at Trump’s “Smart Dollar.” Now they’re all in.
"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the White House just greenlit a $30 trillion upgrade to our financial system. Big firms like JP Morgan and Goldman Sachs are already onboard. And our Wall Street insider expects this change to create more wealth in the next 5 years than major innovations like the computer.tc pixel
Brokerages Set Xencor, Inc. (NASDAQ:XNCR) Target Price at $22.25
Xencor (NASDAQ:XNCR) Coverage Initiated at Barclays
Xencor (NASDAQ:XNCR) Upgraded to Strong Sell at Barclays
See More Xencor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email.

About Xencor

Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics. Xencor’s pipeline features multiple clinical-stage candidates, including bispecific molecules that recruit T cells to tumor cells and antibody therapeutics targeting checkpoint pathways. The company also explores next-generation cytokine fusions designed to improve safety and efficacy profiles over conventional formats.

In advancing its discovery programs, Xencor has established strategic collaborations and licensing agreements with several leading pharmaceutical companies. Partners include Amgen, Pfizer, AstraZeneca and Lilly, among others, which leverage Xencor’s XmAb® platform to generate novel candidates across oncology, inflammation and immunology. Through these partnerships, Xencor’s technology reaches global markets via co-development and commercial licensing arrangements.

Founded in 1997 and headquartered in Monrovia, California, Xencor is led by President and Chief Executive Officer Bassil Dahiyat, Ph.D., who co-founded the company with a vision to harness protein engineering for therapeutic innovation. Over its history, Xencor has grown from a technology-focused startup into a specialized biotech organization advancing multiple clinical programs toward regulatory milestones.

View Xencor Profile

More Earnings Resources from MarketBeat